Journal of Inherited Metabolic Disease

, Volume 30, Issue 3, pp 388–399 | Cite as

Statin therapy depresses total body fat oxidation in the absence of genetic limitations to fat oxidation

  • N. M. Fisher
  • K. Meksawan
  • A. Limprasertkul
  • P. J. Isackson
  • D. R. Pendergast
  • G. D. Vladutiu
Original Article


Cholesterol lowering drugs are associated with myopathic side effects in 7% of those on therapy, which is reversible in most, but not all patients. This study tested the hypothesis that total body fat oxidation (TBFO) is reduced by statins in patients with genetic deficiencies in FO, determined by white blood cells (FOwbc) and by molecular analysis of common deficiencies, and would cause intolerance in some patients. Six patients on statin therapy without myopathic side effects (tolerant) and 7 patients who had previously developed statin-induced myopathic symptoms (intolerant) (age=58 ± 8.25 yrs, ht.=169±11 cm, and wt. = 75.4 ±14.2 kg) were tested for TBFO (Respiratory Exchange Ratio, RER) pre- and during exercise. FOwbc was not significantly different between tolerant and intolerant (0.261 ±0.078 vs. 0.296 ±0.042 nmol/h per 109 wbc), or normals (0.27 ±0.09 nmol/h per 109 wbc) and no common molecular abnormalities were found. Pre-exercise RER (0.73 ±0.05 vs. 0.84 ±0.05) was significantly lower in the intolerant group and the Vo 2 at RER=1.0 (1.27 ±0.32 vs. 1.87±0.60 L/min) greater than the tolerant. Post-exercise lactates were not different between groups. Although dietary fat intake was not different, blood lipoprotein levels, particularly triglycerides were 35% lower in tolerant than previously intolerant. TBFO and blood lipoproteins were reduced in tolerant patients in spite of the absence of genetic limitations, but not in the intolerant group as hypothesized. Although not conclusive, these data suggest the need for a prospective study of the effects of statins on fat oxidation.


Statin Statin Therapy Respiratory Exchange Ratio AMPD Tolerant Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.





creatine kinase


free fatty acids


fat oxidation by white blood cells


high-density lipoprotein cholesterol


hydroxymethylglutaryl-coenzyme A


heart rate


low-density lipoprotein cholesterol


respiratory exchange ratio


total body fat oxidation


total cholesterol




very low-density lipoprotein cholesterol


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anonymous (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486–497.CrossRefGoogle Scholar
  2. Castano G, Mas R, Arruzazabala ML, et al (1999) Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemia patients. Int J Clin Pharm Res 19: 105–116.Google Scholar
  3. Champe PC, Harvey RA, Ferrier DR (2005) Biochemistry, 3rd edn. Philadelphia: Lippincott Williams & Wilkins, 179–198.Google Scholar
  4. Dipietro L, Caspersen CJ, Ostfeld AM, Nadel ER (1993) A survey for assessing physical activity among older adults. Med Sci Sports Exerc 25: 628–642.Google Scholar
  5. Duane WC (1994) Effects of lovastatin and dietary cholesterol on bile acid kinetics and bile lipid composition in healthy male subjects. J Lipid Res 35: 501–509.PubMedGoogle Scholar
  6. Fisher NM, Pendergast DR, Calkins E (1990) Maximal isometric torque of knee extension as a function of muscle length in subjects of advancing age. Arch Phys Med Rehabil 71(10): 729–734.PubMedGoogle Scholar
  7. Foley KA, Massing MW, Simpson RJ Jr, Alexander CM, Markson LE (2004) Population implications of changes in lipid management in patients with coronary heart disease. Am J Cardiol 93: 193–195.CrossRefPubMedGoogle Scholar
  8. Head A, Jakeman PM, Kendall MJ, Cramb R, Maxwell S (1993) The impact of a short course of three lipid lowering drugs on fat oxidation during exercise in healthy volunteers. Postgrad Med J 69(809): 197–203.CrossRefPubMedGoogle Scholar
  9. Hoppeler H, Billeter R, Horvath PJ, Leddy JJ, Pendergast DR (1999) Muscle structure with low and high fat diets in well trained male runners. Int J Sports Med 20(8): 522–526.CrossRefPubMedGoogle Scholar
  10. Horvath PJ, Eagen C, Fisher NM, Leddy JJ, Pendergast DR (2000) The effects of varying dietary fat on performance and metabolism in trained male and female runners. J Am Coll Nutr 19(1): 52–60.PubMedGoogle Scholar
  11. Iliadis EA, Rosenson RS (1999) Long-term safety of pravastatin–gemfibrozil therapy in mixed hyperlipidemia. Clin Cardiol 22:25–28.CrossRefPubMedGoogle Scholar
  12. Lofberg M, Jankala H, Paetau A, Harkonen M, Somer H (1998) Metabolic causes of recurrent rhabdomyolysis. Acta Neurol Scand 98: 268–275.PubMedGoogle Scholar
  13. Langer T, Levy RI (1968) Acute muscular syndrome associated with administration of clofibrate. N Engl J Med 279: 856–858.PubMedCrossRefGoogle Scholar
  14. Meksawan K, Pendergast DR, Vladutiu GD, Awad A (2005) Effect of dietary fat intake on total body and white blood cell fat oxidation in exercised sedentary subjects. Nutr Res 25: 225–237.CrossRefGoogle Scholar
  15. O’Meara JG, Kardia SLR, Armon JL, Brown CA, Boerwinkle E, Tumer ST (2004) Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med 164: 1313–1318.CrossRefPubMedGoogle Scholar
  16. Paolisso G, Barbagallo M, Peterella G, et al (2000) Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent patients. Atherosclerosis 150: 121–127.CrossRefPubMedGoogle Scholar
  17. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lefant C (2002) ACC/AHA/NHLBI Clinical advisory on the use and safety of statins. J Am Coll Cardiol 40: 567–572.CrossRefPubMedGoogle Scholar
  18. Pendergast DR, Fisher NM, Meksawan K, Doubrava M, Vladutiu GD (2004) The distribution of white blood cell fat oxidation in health and disease. J Inherit Metab Dis 27: 1–11.CrossRefGoogle Scholar
  19. Phillips PS, Haas RH, Barshop B, et al (2002) Utility of abnormal 3-methylglutaconic aciduria (3MGA) in diagnosing statin associated myopathy. Atheroscler Thromb Vasc Biol Online J 22: 878.Google Scholar
  20. Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH (2004) Statin myotoxicity is associated with changes in cardiopulmonary function. Atherosclerosis 177: 183–188.CrossRefPubMedGoogle Scholar
  21. Qureshi AA, Peterson DM (2001) The combined efffcts of novel tocotrienols and lovastatin on lipid metabolism in chickens Atherosclerosis 156: 39–47.CrossRefPubMedGoogle Scholar
  22. Rosenson RS (2004) Current overview of statin-induced myopathy. Am J Med 116: 408–416.CrossRefPubMedGoogle Scholar
  23. Rustemeijer C, Schouten JA, Janssens EN, Spooren PF, van Doormaal JJ (1997) Pravastatin in diabetes-associated hypercholesterolemia. Acta Diabetol 34: 294–300.CrossRefPubMedGoogle Scholar
  24. Scharnagl H, Schinker R, Gierens H, Nauck M, Wieland H, Marz W (2001) Effect of atorvasatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol 62: 1545–1555.CrossRefPubMedGoogle Scholar
  25. Schrauwen P, Hoppeler H, Billeter R, Bakker A, Pendergast DR (2001) Fiber type dependent upregulation of human skeletal muscle UCP2 and UPC3 mRNA expression by high-fat diet. Int J Obes 25: 449–456.CrossRefGoogle Scholar
  26. Seargeant LE, Balachandra K, Mallory C, Dilling LA, Greenburg CR (1999) A simple screening test for fatty acid oxidation defects using whole-blood palmitate oxidation. J Inherit Metab Dis 22: 740–746.CrossRefPubMedGoogle Scholar
  27. Smith JL, Roach PD, Wittenberg LN, et al (2000) Effect of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol 15: 871–879.CrossRefPubMedGoogle Scholar
  28. Staels B, van Tol A, Fruchart JC, Auwerx J (1996) Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat Israel J Med Sci 32: 490–498.PubMedGoogle Scholar
  29. Teo KK, Burton JR, Buller CE, et al (2000) Long-term effects of cholesterol lowering and angiotensin-converting enzymes inhibition on coronary atherosclerosis: the Simvastating/Enalapril Coronary Atherosclerosis Trial (SCAT) Circulation 102: 1748–1754.PubMedGoogle Scholar
  30. Vladutiu GD, Bennett MJ, Fisher NM, Small DS, Leddy JJ, Pendergast DR (2002) Phenotypic variability among first-degree relatives with the same mutations in the carnitine palmitoyltransferase II gene. Muscle Nerve 26(4): 492–498.CrossRefPubMedGoogle Scholar
  31. Wilmore JH, Costill DL (2004) Physiology of Sport and Exercise, 3rd. edn. Champaign, IL: Human Kinetics, 118–139, 184–186.Google Scholar
  32. Zambon D, Ros E, Rodriguez-Villar C, et al (1999) Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidema: additive effects of combination treatment on lipid regulation. Metabolism 48: 47–54.CrossRefPubMedGoogle Scholar

Copyright information

© SSIEM and Springer 2007

Authors and Affiliations

  • N. M. Fisher
    • 1
  • K. Meksawan
    • 7
  • A. Limprasertkul
    • 2
  • P. J. Isackson
    • 3
  • D. R. Pendergast
    • 4
  • G. D. Vladutiu
    • 3
    • 5
    • 6
  1. 1.Department of Rehabilitation Science, School of Public Health and Health ProfessionsUniversity at BuffaloBuffaloUSA
  2. 2.Department of Exercise and Nutrition SciencesUniversity at BuffaloBuffaloUSA
  3. 3.Department of PediatricsUniversity at BuffaloBuffaloUSA
  4. 4.Department of Physiology and BiophysicsUniversity at BuffaloBuffaloUSA
  5. 5.Department of PathologyUniversity at BuffaloBuffaloUSA
  6. 6.Department of NeurologyUniversity at BuffaloBuffaloUSA
  7. 7.Faculty of Pharmaceutical Sciences at Chulalongkorn UniversityBangkokThailand

Personalised recommendations